share_log

CORRESP: CORRESP

SEC announcement ·  May 29 10:35
Summary by Futu AI
Apollomics Inc., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The company seeks to have the registration become effective on May 29, 2024, at 4:00 p.m. Eastern Time. This request was made in accordance with Rule 461 of Regulation C under the Securities Act of 1933. Apollomics has indicated that the effective date may be adjusted if necessary, based on further communication with the SEC. The company's legal counsel, Ryan Coombs from O'Melveny & Myers LLP, is the primary contact for this matter, with Yoon-jee Kim available in his absence.
Apollomics Inc., a biopharmaceutical company, has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The company seeks to have the registration become effective on May 29, 2024, at 4:00 p.m. Eastern Time. This request was made in accordance with Rule 461 of Regulation C under the Securities Act of 1933. Apollomics has indicated that the effective date may be adjusted if necessary, based on further communication with the SEC. The company's legal counsel, Ryan Coombs from O'Melveny & Myers LLP, is the primary contact for this matter, with Yoon-jee Kim available in his absence.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.